Preferred Label : Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101;
NCIt synonyms : ADC HDP-101; Anti-BCMA Antibody-drug Conjugate HDP-101; Anti-BCMA/Alpha-amanitin ADC HDP-101;
NCIt definition : An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against the tumor-associated
antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) conjugated, via a cleavable
linker, to the cytotoxic, RNA polymerase II inhibitor alpha-amanitin, with potential
antineoplastic activity. Upon administration of anti-BCMA/alpha-amanitin ADC HDP-101,
the antibody moiety targets and binds to the cell surface antigen BCMA expressed on
certain cancer cells. Upon antibody/antigen binding, internalization and cleavage,
the cytotoxic alpha-amanitin is released. Alpha-amanitin binds to and inhibits RNA
polymerase II, prevents RNA synthesis, induces apoptosis, and inhibits the proliferation
of BCMA-overexpressing tumor cells. BCMA, a receptor for a proliferation-inducing
ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell
activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor
superfamily and plays a key role in plasma survival; it is found on the surfaces of
plasma cells and is overexpressed on malignant plasma cells.;
Molecule name : HDP-101; HDP 101;
NCI Metathesaurus CUI : CL1662215;
Origin ID : C179409;
UMLS CUI : C5555666;
Semantic type(s)
- concept_is_in_subset
- has_target
